These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 25907508

  • 1. Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor.
    D'Alessandro R, Refolo MG, Lippolis C, Carella N, Messa C, Cavallini A, Carr BI.
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1237-1245. PubMed ID: 25907508
    [Abstract] [Full Text] [Related]

  • 2. Resistance to multikinase inhibitor actions mediated by insulin like growth factor-1.
    Lippolis C, Refolo MG, D'Alessandro R, Carella N, Messa C, Cavallini A, Carr BI.
    J Exp Clin Cancer Res; 2015 Sep 02; 34(1):90. PubMed ID: 26329608
    [Abstract] [Full Text] [Related]

  • 3. Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines.
    D'Alessandro R, Refolo MG, Lippolis C, Giannuzzi G, Carella N, Messa C, Cavallini A, Carr BI.
    BMC Cancer; 2014 May 21; 14():351. PubMed ID: 24885890
    [Abstract] [Full Text] [Related]

  • 4. Regorafenib induces extrinsic and intrinsic apoptosis through inhibition of ERK/NF-κB activation in hepatocellular carcinoma cells.
    Tsai JJ, Pan PJ, Hsu FT.
    Oncol Rep; 2017 Feb 21; 37(2):1036-1044. PubMed ID: 28000898
    [Abstract] [Full Text] [Related]

  • 5. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
    Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Evers BM.
    J Surg Res; 2012 Aug 21; 176(2):542-8. PubMed ID: 22261591
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
    Liao YJ, Hsu SM, Chien CY, Wang YH, Hsu MH, Suk FM.
    Molecules; 2020 Jun 20; 25(12):. PubMed ID: 32575795
    [Abstract] [Full Text] [Related]

  • 14. Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.
    Gu HR, Park SC, Choi SJ, Lee JC, Kim YC, Han CJ, Kim J, Yang KY, Kim YJ, Noh GY, No SH, Jeong JH.
    Clin Mol Hepatol; 2015 Mar 20; 21(1):49-59. PubMed ID: 25834802
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.
    Wei JC, Meng FD, Qu K, Wang ZX, Wu QF, Zhang LQ, Pang Q, Liu C.
    Acta Pharmacol Sin; 2015 Feb 20; 36(2):241-51. PubMed ID: 25557114
    [Abstract] [Full Text] [Related]

  • 19. Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma.
    Sieghart W, Pinter M, Dauser B, Rohr-Udilova N, Piguet AC, Prager G, Hayden H, Dienes HP, Dufour JF, Peck-Radosavljevic M.
    J Hepatol; 2012 Sep 20; 57(3):592-9. PubMed ID: 22634341
    [Abstract] [Full Text] [Related]

  • 20. Receptor tyrosine kinase inhibition by regorafenib/sorafenib inhibits growth and invasion of meningioma cells.
    Tuchen M, Wilisch-Neumann A, Daniel EA, Baldauf L, Pachow D, Scholz J, Angenstein F, Stork O, Kirches E, Mawrin C.
    Eur J Cancer; 2017 Mar 20; 73():9-21. PubMed ID: 28082204
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.